Novus Therapeutics, Inc (NVUS) PT Lowered to $3.25 at Ascendiant Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts NVUS Hot Sheet
Price: $14.60 --0%
Rating Summary:
3 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 18
Rating Summary:
3 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 18
Join SI Premium – FREE
Ascendiant Capital analyst Edward Woo lowered the price target on Novus Therapeutics, Inc (NASDAQ: NVUS) to $3.25 (from $3.50) while maintaining a Buy rating.
You May Also Be Interested In
- Applied Industrial Technologies (AIT) PT Lowered to $360 at KeyBanc
- Brown & Brown (BRO) PT Lowered to $85 at Truist Securities
- PrairieSky Royalty Ltd (PSK:CN) (PREKF) PT Raised to Cdn$38.75 at CIBC
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
